Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to improvements in the treatment of cancer patients. However, not every cancer responds to radiotherapy in the same way. Despite applying uniform treatment protocols for radiotherapy to minimize damage to the surrounding healthy tissue, a large patient-to-patient variability exists in radiation-induced toxicities. Many cancer patients achieve survivorship at the cost of treatment complications occurring in normal tissues. However, the solution is not to eliminate radiation exposure but to protect individuals who are the most sensitive to radiation and minimize dose and exposure to all individuals.In this thesis, I focused on uncovering the under...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
BACKGROUND: This study was designed to identify common genetic susceptibility and shared genetic var...
Purpose: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
Cancer remains a leading cause of death globally, and radiotherapy has contributed significantly to ...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
BACKGROUND: This study was designed to identify common genetic susceptibility and shared genetic var...
Purpose: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
PURPOSE: A two-stage genome-wide association study was carried out in head and neck cancer (HNC) pat...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...
Radiogenomics Consortium was established in Manchester, United Kingdom, November 17 and 18, 2009, in...